Insider Transactions in Q1 2023 at Adaptive Biotechnologies Corp (ADPT)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2023
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
2,341
-10.19%
|
$18,728
$8.49 P/Share
|
|
Mar 07
2023
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
9,813
-4.07%
|
$78,504
$8.6 P/Share
|
|
Mar 07
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,155
-8.77%
|
$137,240
$8.6 P/Share
|
|
Mar 07
2023
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,387
-8.75%
|
$107,096
$8.6 P/Share
|
|
Mar 06
2023
|
Kyle Piskel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,529
-1.94%
|
$28,232
$8.58 P/Share
|
|
Mar 06
2023
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,735
+32.44%
|
-
|
|
Mar 06
2023
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+36.32%
|
-
|
|
Mar 06
2023
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+16.28%
|
-
|
|
Mar 06
2023
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+36.32%
|
-
|
|
Mar 06
2023
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,775
+39.15%
|
-
|
|
Mar 06
2023
|
Chad M Robins CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+13.51%
|
-
|
|
Mar 06
2023
|
Harlan S Robins Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
354,610
+34.73%
|
-
|
|
Mar 06
2023
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
22,668
-6.31%
|
$181,344
$8.57 P/Share
|
|
Mar 06
2023
|
Julie Rubinstein President |
BUY
Grant, award, or other acquisition
|
Direct |
132,979
+27.0%
|
-
|
|
Mar 06
2023
|
Nitin Sood Chief Commercial Officer, MRD |
SELL
Open market or private sale
|
Direct |
6,661
-2.69%
|
$53,288
$8.57 P/Share
|
|
Mar 06
2023
|
Nitin Sood Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
132,979
+34.95%
|
-
|
|
Mar 06
2023
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
11,749
-4.99%
|
$93,992
$8.57 P/Share
|
|
Mar 06
2023
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
132,979
+36.08%
|
-
|
|
Mar 06
2023
|
Tycho Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,203
+19.34%
|
-
|
|
Mar 06
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,529
-3.23%
|
$52,232
$8.57 P/Share
|
|
Mar 06
2023
|
R Mark Adams Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
88,652
+30.48%
|
-
|
|
Mar 06
2023
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
5,491
-3.46%
|
$43,928
$8.57 P/Share
|
|
Mar 06
2023
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
85,697
+35.09%
|
-
|
|
Mar 06
2023
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
6,816
-3.89%
|
$54,528
$8.57 P/Share
|
|
Mar 06
2023
|
Francis Lo Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,697
+32.84%
|
-
|
|
Feb 02
2023
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
53,000
+46.41%
|
$0
$0.45 P/Share
|
|
Jan 10
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,130
-1.84%
|
$17,040
$8.58 P/Share
|
|
Jan 09
2023
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
995
-0.85%
|
$7,960
$8.5 P/Share
|